

Real-world evidence data reveals the physicians' perception on erenumab therapy in German headache centers



Scan to download a copy of this presentation

Mirja Koch* ¹, Katrin Schuh¹, Charly Gaul², Philipp Stude³, Andreas Straube⁴

¹Clinical Research Neuroscience, Novartis Pharma GmbH, Nuremberg, Germany ²Migraine and Headache Clinic, Koenigstein am Taunus, Germany;

³Neurologische Praxis Dr. Stude, Bochum, Germany, ⁴Ludwig-Maximilians-University, Munich, Germany

Migraine Trust Virtual Symposium, 3–9 October, 2020

This study is supported by Novartis Pharma GmbH, Germany. Erenumab is co-developed by Amgen and Novartis.


Parts of this data were previously presented at 72st Annual Meeting of American Academy of Neurology, April 25–May 1, 2020



Background and Results

- TELESCOPE was an online survey (July 2019 – December 2019) of 45 headache centers in Germany:
 - Capturing the treating-physician's perspective on erenumab treatment with regards to therapy decision, patient profiles and quality of life (QoL) of the patients
 - Documentation of treatment effects and satisfaction with outcome of 10-20 individual episodic and chronic migraine patients with at least three months of erenumab treatment per site (in total 542 patients were documented)
- A concurrent project evaluated response and subjective judgement of patients (PERSICOPE; see MTIS DP-043)

Figure 1. Reasons for treatment initiation with monoclonal antibodies



- More than half of the physicians considered restricted QoL, monthly migraine days (MMD) and number of previous prophylactic treatments very important in deciding to initiate treatment with monoclonal antibodies



Results

- Treating physicians observed reduced migraine burden and improved quality of life in more than 75% of their patients after treatment with erenumab
- Response rate and patient satisfaction were both reported as high

Figure 2. Erenumab effects and satisfaction









Figure 3. Erenumab effects on migraine specific parameters and onset of effect



- TELESCOPE provides us with real-world evidence data for erenumab in Germany
- Based on the assessment of treating physicians, erenumab reduces the burden of migraine and increases the quality of life in more than 75% of their patients, with an onset after first injection in a majority of the patients.